Your browser doesn't support javascript.
loading
COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies.
Di Fusco, Manuela; Lin, Jay; Vaghela, Shailja; Lingohr-Smith, Melissa; Nguyen, Jennifer L; Scassellati Sforzolini, Thomas; Judy, Jennifer; Cane, Alejandro; Moran, Mary M.
Afiliación
  • Di Fusco M; Pfizer Inc., New York, NY, USA.
  • Lin J; Novosys Health, Green Brook, NJ, USA.
  • Vaghela S; HealthEcon Consulting Inc., Ancaster, ON, Canada.
  • Lingohr-Smith M; Novosys Health, Green Brook, NJ, USA.
  • Nguyen JL; Pfizer Inc., New York, NY, USA.
  • Scassellati Sforzolini T; Pfizer Inc., New York, NY, USA.
  • Judy J; Pfizer Inc., New York, NY, USA.
  • Cane A; Pfizer Inc., New York, NY, USA.
  • Moran MM; Pfizer Inc., Collegeville, PA, USA.
Expert Rev Vaccines ; 21(4): 435-451, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35112973
INTRODUCTION: From July through October of 2021, several countries issued recommendations for increased COVID-19 vaccine protection for individuals with one or more immunocompromised (IC) conditions. It is critically important to understand the vaccine effectiveness (VE) of COVID-19 vaccines among IC populations as recommendations are updated over time in response to the evolving COVID-19 pandemic. AREAS COVERED: A targeted literature review was conducted to identify real-world studies that assessed COVID-19 VE in IC populations between December 2020 and September 2021. A total of 10 studies from four countries were identified and summarized in this review. EXPERT OPINION: VE of the widely available COVID-19 vaccines, including BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), Ad26.COV2.S (Janssen), and ChAdOx1 nCoV-19 (Oxford/AstraZeneca), ranged from 64% to 90% against SARS-CoV-2 infection, 73% to 84% against symptomatic illness, 70% to 100% against severe illness, and 63% to 100% against COVID-19-related hospitalization among the fully vaccinated IC populations included in the studies. COVID-19 VE for most outcomes in the IC populations included in these studies were lower than in the general populations. These findings provide preliminary evidence that the IC population requires greater protective measures to prevent COVID-19 infection and associated illness, hence should be prioritized while implementing recommendations of additional COVID-19 vaccine doses.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Expert Rev Vaccines Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Expert Rev Vaccines Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido